Urokinase-type plasminogen activator system predicts risk of cardiovascular events in patients with angina pectoris: results of the ECAPTURE study. European Concerted Action on Prevention from Thrombosis by URokinase Enhancement.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Lippincott Williams And Wilkins Country of Publication: England NLM ID: 9102551 Publication Model: Print Cited Medium: Print ISSN: 0957-5235 (Print) Linking ISSN: 09575235 NLM ISO Abbreviation: Blood Coagul Fibrinolysis Subsets: MEDLINE
    • Publication Information:
      Publication: London : Lippincott Williams And Wilkins
      Original Publication: Oxford, UK : Rapid Communications of Oxford Ltd., c1990-
    • Subject Terms:
      Angina Pectoris/*blood ; Cardiovascular Diseases/*blood ; Urokinase-Type Plasminogen Activator/*blood; Angiography ; Enzyme-Linked Immunosorbent Assay ; Europe ; Female ; Humans ; Male ; Middle Aged ; Quality Control ; Reference Values ; Risk Factors
    • Abstract:
      In most Westernized societies cardiovascular diseases are the leading cause of death over the age of 45 years and one-quarter of these deaths occur in men below the age of 65 years. The haemostasis system has been identified as an important system in cardiovascular disease (CVD). The European Concerted Action on Prevention from Thrombosis by URokinase Enhancement (ECAPTURE) has focused on the contribution of the urokinase system to CVD. In 2298 patients with angina pectoris the relationship between plasma levels of single-chain urokinase (scu-PA), urokinase antigen (u-PA) and u-PA-inhibitor complex and the risk of cardiovascular events (n = 84) during a 2 year follow-up period was studied. Plasma levels of total u-PA and u-PA-inhibitor complex predicted the risk of cardiovascular events, the adjusted relative risks of the highest quintile versus the lowest were 2.71 [95% confidence interval (CI), 1.34-5.48] and 2.34 (95% CI, 1.08-5.11), respectively. These results suggest that the urokinase system plays a role in cardiovascular disease.
    • Accession Number:
      EC 3.4.21.73 (Urokinase-Type Plasminogen Activator)
    • Publication Date:
      Date Created: 20010914 Date Completed: 20011204 Latest Revision: 20190915
    • Publication Date:
      20231215
    • Accession Number:
      10.1097/00001721-200109000-00005
    • Accession Number:
      11555698